NewsBenzingaNeOnc Technologies plant FDA-In-Person-End-of-Phase-1-Typ-B-Meeting bezüglich NEO212 für den 17. November NeOnc Technologies plant FDA-In-Person-End-of-Phase-1-Typ-B-Meeting bezüglich NEO212 für den 17. November Benzinga 2026.09.28 12:06 (GMT+0) Open on Benzinga Other news Israeli Shipping Giant ZIM Cashes In on Surging Freight Rates, Raises Outlook UBS Maintains Buy on Home Depot, Lowers Price Target to $417 Disney Posts Upbeat Q4, Analysts Raise Price Target Citing Theme Park Resilience StoneX Maintains Buy on Bitdeer Techs, Lowers Price Target to $15 Merck Pulls Plug On Acquired Drug after Safety Review UBS Maintains Neutral on Granite Point Mortgage Tr, Lowers Price Target to $3